47 resultados.
Currently, the Finlay Vaccine Institute is accelerating the development of the candidates Quimi-Vio 11 (in phase II-III clinical trials) and Quimi-Vio 16, with the aim of protecting the most vulnerable population through conjugation technology of proven efficacy and safety
The United Nations system sponsors Regional Earthquake Response Simulation in Cuba
Cuban ongoing projects to have a system for rapid diagnosis of dengue and a preventive vaccine against this disease show important advances, which could translate into concrete results for this year, confirmed authorities of the Business Group of the Biotechnological and Pharmaceutical Industries (BioCubaFarma in Spanish).
After several months of research, a multidisciplinary team of scientists has released new information about the devastating tornado that struck five Havana municipalities, January 27, this year
This placebo-controlled, double-blind trial includes patients with moderate rheumatoid arthritis
The National Center for Scientific Research has the status of High Technology Enterprise
Just months after Cuba detected its first positive case of COVID-19, the country already had a specific vaccine candidate—exactly five years ago today
Industrial production has begun of Cuba’s candidate vaccines Soberana 02 and Abdala (CIGB-66), two of the four developed on the island to combat COVID-19, with progress advancing at BioCubaFarma facilities
The Center for Immunoassay (CIE) and the Beijing Institute of Technology (BIT) signed in Havana a memorandum of understanding for the creation of a joint laboratory in the Asian country, focused on expanding academic scientific collaboration
Data shows that only 5.5% of patients treated with Heberon developed serious complications
